Search
Histamine
go.drugbank.com/drugs/DB05381ApprovedInvestigationalIt is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. … A depressor amine derived by enzymatic decarboxylation of histidine.
Mixtures: MIKES Ponos Pain Relief Cream Roll-OnCategories: Tests for Gastric SecretionStrontium chloride
go.drugbank.com/drugs/DB13987ApprovedWithdrawnSrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession [A33167, A33168]. … Such strontium chloride toothpaste formulations may subsequently not be available for sale anymore in certain parts of the world [A33167, A33168].
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedIn addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS]. … Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis.
Categories: Compounds used in a research, industrial, or household setting, Vitamin ESynonyms: VITAMIN E POLYETHYLENE GLYCOL SUCCINATE, VITAMIN E POLYETHYLENE GLYCOL 1000 SUCCINATEHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineProducts: Hydroxycarbamid 1A Pharma 100 mg - Filmtabletten, Hydroxycarbamid 1A Pharma 1000 mg - FilmtablettenVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.
Ditiocarb zinc
go.drugbank.com/drugs/DB14193ApprovedDitiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen. … Sensitivity to ditiocarb zinc may be identified with a clinical patch test.
Categories: Compounds used in a research, industrial, or household setting, Agents for Treatment of Hemorrhoids and Anal Fissures for Topical UseSynonyms: Zinc N,N-diethyldithiocarbamateReboxetine
go.drugbank.com/drugs/DB00234ApprovedInvestigationalWithdrawnReboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. … Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra.
Gemcitabine
go.drugbank.com/drugs/DB00441ApprovedInvestigationalGemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. … [A233135] Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose.
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: UNIGEM-Gemcitabine 38mg/mL concentrate for solution for Infusion, PAMIGEN® 200MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIONINYECTABLEFerric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigational[A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency. … [A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnMarginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … [A229668] On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results